Amarin Corp Plc (AMRN)

[everyonesguess]

From the presentation (slide #3) for Dec/15 Oppenheimer CC:

"Upcoming: Cardiovascular outcomes data on Vascepa® (>96% ethyl-EPA3) as add-on to statins ? REDUCE-IT CV outcomes study 99% enrolled ? Events driven study incorporates learnings from positive JELIS (Japan CV outcomes study of EPA) and others ? Leverages strong lipid efficacy & safety profile: two Phase 3s ? Studying at-risk patients with persistent elevated triglycerides ? CV outcomes results expected 2018, potentially 2016"

The company said they expect 967th occurring in 1H16.

And later 967th indicates higher RRR.